Search company, investor...



Other Investors | Alive

About Eximias

Eximias is developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA

Headquarters Location

Berwyn, Pennsylvania, 19312,

United States

Missing: Eximias's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Eximias's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Eximias

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Eximias is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Eximias Frequently Asked Questions (FAQ)

  • Where is Eximias's headquarters?

    Eximias's headquarters is located at Berwyn.

  • What is Eximias's latest funding round?

    Eximias's latest funding round is Other Investors.

  • Who are the investors of Eximias?

    Investors of Eximias include Quaker BioVentures.

  • Who are Eximias's competitors?

    Competitors of Eximias include Igenica Biotherapeutics, Forte Biosciences, AnaptysBio, Collegium Pharmaceutical, Veracyte and 12 more.

Compare Eximias to Competitors

Falcon Genomics

Falcon Genomics, Inc. is focused on functional genomics as a tool for cancer diagnostics and therapeutics.

TenX Biopharma

TenX is a biopharmaceutical company focused on late stage development and launch of novel cancer products.


Sopherion is a therapeutics platform company initially focused on cancer.

Pro-Cure Therapeutics

Prostate Cancer - Pro-Cure Therapeutics - Enabling the development of a cure for prostate cancer based on stem cells


Neomics is a drug discovery and diagnostics company with a unique cancer target and biomarker discovery platform. In particular, Neomics is focused on novel targets and biomarkers relevant to aminoacyl RNA synthetases (ARS). They have preclinical and clinical validation of their targets and biomarkers.


NanoMedica aims to become engaged in design,development and manufacture of dual-action therapeutics for the treatment of human cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.